Lurbinectedin (PM01183; PM-01183; Zepzelca) is a covalent DNA minor groove binder with potent anticancer activity. It acts by covalently binding to residues lying in the minor groove of DNA, leading to delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death. Lurbinectedin has been approved in2020 for the treatment of adults with metastatic small cell lung cancer.

纯度：≥98%

CAS：497871-47-3